Published: March 2025 | Last updated: May 2026
Chlamydia is the most commonly reported bacterial sexually transmitted infection in the United States, with more than 1.5 million cases reported to the CDC in its 2024 STI surveillance data. Most of those people had no symptoms at all. They learned they were infected only because they got screened during a routine sexual-health visit, or because a partner tested positive and contacted them.
That asymptomatic pattern is why public-health agencies recommend screening on a schedule rather than testing only when something feels wrong. Waiting for symptoms misses most infections, and the longer chlamydia goes untreated, the higher the chance it spreads onward or causes complications like pelvic inflammatory disease and tubal infertility.
This guide walks through who the CDC and the U.S. Preventive Services Task Force recommend for testing, how often, what testing looks like in a clinic versus at home, and what to do if your result comes back positive. No moralizing, no scare tactics, just the current guidance and how to apply it.
Who the CDC and USPSTF say should get tested
Two U.S. authorities publish formal chlamydia screening guidance: the Centers for Disease Control and Prevention, and the U.S. Preventive Services Task Force. Both reach similar conclusions with slightly different framing.
The USPSTF gives chlamydia screening a Grade B recommendation, meaning there is at least fair evidence that the net benefit is moderate to substantial. Insurance plans subject to the Affordable Care Act must cover Grade A and B preventive services with no cost-sharing, which is why annual chlamydia screening is typically free for in-network patients who ask for it. That is one of the most overlooked practical facts about screening: in most cases, the test does not cost the patient anything.
USPSTF guidance is anatomy-based rather than gender-identity-based, so the recommendations that follow apply to anyone with the relevant anatomy. A trans man with a cervix, for example, falls under the same screening guidance as a cisgender woman of the same age and risk profile.
Here is how the recommendations break down by group:
- Sexually active women (and people with a cervix) under 25: annual screening, regardless of perceived risk. This is the largest group covered by routine guidance and the one with the strongest evidence base.
- Women 25 and older with risk factors: annual screening when there are new or multiple partners, a partner with a known STI, or inconsistent condom use.
- Pregnant women under 25, or older pregnant women with risk factors: screen at the first prenatal visit; retest in the third trimester for those at continued risk.
- Men who have sex with men: annual screening at all sites of sexual contact (urethra, rectum, pharynx), and every 3 to 6 months if at increased risk or living with HIV.
- Anyone with a partner diagnosed with chlamydia: test regardless of symptoms.
- Anyone with symptoms (unusual discharge, burning during urination, pelvic pain, testicular pain, rectal pain or discharge): test promptly, ideally the same week.
Notice what is not on that list: routine screening for asymptomatic men in the general population. The current USPSTF position is that evidence is insufficient to recommend universal screening of asymptomatic men outside of higher-risk groups. The CDC takes a more flexible view and notes that screening sexually active young men in clinical settings with a high chlamydia burden (adolescent clinics, correctional facilities, STD clinics) can be appropriate. If you are a man under 25 with new partners, the practical answer is to ask your provider; many clinics will screen on request, and the test itself is non-invasive.
Who should get tested for chlamydia, and how often?
Annual screening is recommended for all sexually active women under 25, women 25+ with new or multiple partners, men who have sex with men (at every site of contact), pregnant women under 25 or with risk factors, and anyone whose partner tested positive. Retest 3 months after any positive result, and at every new-relationship transition rather than strictly on a calendar.
Why most chlamydia goes undetected
The single biggest reason people skip testing is that they feel completely fine. The CDC's STI Treatment Guidelines describe asymptomatic infection as common in both men and women, and published estimates put the rate at roughly 70% in women and around half of men. The practical effect is the same: the infection is silently transmissible for weeks to months before anyone notices something is off.
When symptoms do appear, they are usually mild and easy to attribute to something else. In women, that can mean light bleeding between periods, increased vaginal discharge, or low pelvic discomfort that resembles ordinary cycle pain. In men, it can mean clear or cloudy urethral discharge and burning during urination. Rectal infections can produce pain, bleeding, or discharge but often produce nothing at all. Throat infections almost always feel like nothing.
The clinical pattern this produces is consistent across primary-care settings: women are diagnosed during routine annual gynecological visits, partners of diagnosed individuals are caught through contact tracing, and many male infections only surface when a partner tests positive first. That is the practical reason routine screening matters more than self-monitoring for symptoms you are unlikely to notice.
- Cervical or vaginal infection: light bleeding between periods, increased discharge, low pelvic discomfort, or nothing at all.
- Urethral infection (men): clear or cloudy discharge and burning during urination, or nothing at all.
- Rectal infection: pain, bleeding, or discharge in some cases; frequently asymptomatic.
- Pharyngeal (throat) infection: almost always produces no symptoms.
What chlamydia testing actually involves
Laboratory chlamydia testing uses nucleic acid amplification tests, known as NAATs, which detect bacterial DNA directly from a sample. NAATs are the laboratory gold standard for chlamydia because they are highly sensitive across a wide range of sample types and can find infection even when bacterial loads are low.
The most common sample types are:
- First-catch urine: convenient for men and increasingly used for women too. The first 20 to 30 mL of urine after at least one hour without urinating.
- Vaginal swab: self-collected or provider-collected. Self-collected swabs perform comparably to provider-collected for chlamydia detection, which is part of why home swab testing has gained traction.
- Endocervical swab: collected during a pelvic exam.
- Rectal swab: collected when receptive anal exposure is reported.
- Pharyngeal swab: collected when receptive oral exposure is reported.
Most clinics will only test the site that matches your reported exposure. If you have had receptive anal or oral sex with new partners, ask specifically for rectal or pharyngeal swabs; genital-only testing will miss infection at those sites. The CDC's STI Treatment Guidelines recommend annual rectal screening for men who have sex with men, and the same logic applies to anyone reporting that exposure pattern.
One practical note about throat and rectal testing: our site sells home swab tests validated for genital sampling. For pharyngeal or rectal screening specifically, a clinic visit is the right path. The home rapid kit handles the more common genital screening scenario.
At-home testing and where it fits
Home testing for chlamydia has expanded substantially. Two main formats exist and they are not equivalent technologies, so it is worth knowing the difference before you order one.
Lab-processed mail-in kits use the same NAAT chemistry as a clinic test. You collect a sample at home (urine or vaginal swab depending on the kit), ship it in a prepaid envelope, and receive results from a partner lab in 3 to 7 days. The technology behind the result is the lab gold standard; the only thing that changes is who collects the sample.
Rapid lateral-flow home tests, like the kit sold here, use immunoassay chemistry on a self-collected swab and return a visible result in about 15 minutes. Rapid lateral-flow tests are useful for fast, private first answers, and a positive result is a strong signal to act on quickly. They are not analytically equivalent to lab NAATs, which is a meaningful difference, especially at low bacterial loads or very early in infection.
The workflow most clinicians suggest combines both: use a rapid home test when you want a fast first answer in private, then confirm a positive result with a lab NAAT through your provider before starting antibiotics. A negative rapid result is usually reassuring but does not rule out very recent exposure (within the last 1 to 2 weeks).
What happens if you skip testing
The biggest individual cost of untreated chlamydia is reproductive. In women, the bacterium can ascend from the cervix into the uterus and fallopian tubes, causing pelvic inflammatory disease (PID). The CDC describes PID as a serious complication that can scar the fallopian tubes in ways that lead to ectopic pregnancy or infertility, sometimes years later when someone tries to conceive. Published clinical estimates suggest a meaningful minority of women with untreated chlamydia develop PID, though exact rates vary across studies.
In men, untreated chlamydia can cause epididymitis, an inflammation of the tube behind the testicle that produces pain and swelling. Reactive arthritis is a rarer downstream complication that can occur in either sex and typically involves joint pain, eye inflammation, and urinary symptoms appearing weeks after the initial infection.
During pregnancy, chlamydia raises the risk of preterm birth and can transmit to the infant during delivery, causing conjunctivitis or pneumonia. The CDC recommends prenatal screening at the first visit for all pregnant women under 25 and for older pregnant women with risk factors, with a third-trimester repeat for those at continued risk.
None of these complications are inevitable, and none are common in the population that gets screened. They are concentrated almost entirely in people who never test and never know they were carrying the infection.
Sexually active women younger than 25 years should be tested for chlamydia and gonorrhea every year. Older women with risk factors such as new or multiple sex partners should also be tested every year.
After a positive result: treatment and partners
Chlamydia is curable. The CDC's current first-line treatment is a 7-day course of oral doxycycline (100 mg twice daily), with azithromycin as an alternative when doxycycline is contraindicated (during pregnancy, for example). Treatment is short, well tolerated by most people, and highly effective when taken as prescribed.
Three follow-up actions matter after a positive result. They are summarized below, and the clinical workflow is short, the medication is affordable, and treating early prevents the complications outlined in the section above.
Prevention and how often to retest
Condoms used consistently and correctly substantially reduce the risk of chlamydia transmission, though they are not 100% protective because contact with surrounding skin and shared sex toys can also transmit the bacterium. Reducing the number of new partners and being aware of a partner's recent testing history are the other major levers most people have available.
For people in stable relationships where both partners have been recently tested and are mutually monogamous, annual screening is not strictly required under USPSTF guidance, though many clinicians still suggest periodic testing as part of a general sexual-health check. The recommendation is risk-based, not age-locked once you pass 25.
For everyone else, the practical default is: annual screening if you are sexually active and under 25, more often if you have multiple partners or a partner with an STI, and a retest 3 months after any positive result. The CDC also recommends screening at every new sexual relationship transition rather than only on a calendar schedule, because the transition itself is the actual risk event.
Frequently asked questions
- Does insurance cover chlamydia testing?
- In most cases, yes. The USPSTF gives chlamydia screening a Grade B recommendation, and ACA-compliant insurance plans must cover Grade A and B preventive services with no cost-sharing for in-network providers. Annual screening for women under 25 is one of the most consistently covered preventive tests in U.S. healthcare. Ask your clinic to bill it as a preventive screening rather than a diagnostic visit to maximize coverage.
- How long after exposure should I wait to test?
- The CDC suggests that NAAT testing can detect chlamydia 1 to 2 weeks after exposure. A test taken within the first few days of exposure may produce a false negative because bacterial loads are still building. If you tested within a few days of a possible exposure and the result was negative, repeat the test 2 to 3 weeks later for a more reliable answer.
- Can I get chlamydia from oral sex?
- Yes. Chlamydia can infect the throat (pharyngeal infection) through receptive oral sex, and most pharyngeal infections are asymptomatic. If you have had receptive oral sex with new partners, ask your clinic for a throat swab; the home swab kits sold here are validated for genital sampling, not pharyngeal.
- What is the difference between a home rapid test and a lab NAAT?
- Lab NAATs detect bacterial DNA directly and are the analytical gold standard; results take 3 to 7 days. Rapid lateral-flow home tests use immunoassay chemistry on a self-collected swab and return a visible result in about 15 minutes. The rapid test is faster and more private; the lab NAAT is more sensitive at low bacterial loads. A positive rapid result is a strong reason to follow up with a lab confirmation.
- Do I need to retest after I am treated?
- Yes. The CDC recommends a retest about 3 months after completing treatment, because the most common cause of a repeat positive is reinfection from an untreated partner, not antibiotic failure. A separate test of cure at 4 weeks may be ordered in pregnancy or other specific situations, but the 3-month retest applies to everyone.
- Can men ask for chlamydia screening even if it is not routinely recommended?
- Yes. The current USPSTF position is that evidence is insufficient to recommend universal screening of asymptomatic men in the general population, but the CDC supports screening sexually active young men in higher-burden clinical settings. If you are a man under 25 with new partners, most clinics will screen on request, and many home test kits ship to anyone of any sex who orders one.
- Is chlamydia testing confidential for teenagers?
- In every U.S. state, minors can consent to STI testing and treatment without parental notification, though the specifics around insurance billing and parental notification vary by state. If billing through a parent's insurance is a concern, ask the clinic about confidentiality protections, or look into Title X-funded clinics, which provide free or sliding-scale STI services and stronger confidentiality.
- How accurate are home chlamydia tests?
- Lab-processed mail-in NAAT kits perform comparably to in-clinic NAATs because the underlying chemistry is the same. Rapid lateral-flow home tests are slightly less sensitive, especially at low bacterial loads, so they are best used as a fast-screening tool with lab confirmation for positives. Check each kit's data sheet for its published sensitivity and specificity figures.
- U.S. Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance, 2024: provisional annual data, including the U.S. chlamydia case count of 1,515,985 for 2024.
- U.S. Centers for Disease Control and Prevention. About chlamydia: overview of transmission, symptoms, and complications including pelvic inflammatory disease, ectopic pregnancy, and infertility.
- U.S. Preventive Services Task Force. Final recommendation statement: chlamydia and gonorrhea screening for adolescents and adults, including the Grade B recommendation for women under 25.
- U.S. Centers for Disease Control and Prevention. STI Treatment Guidelines: chlamydia chapter, covering the doxycycline first-line regimen, the 3-month retest interval, and rectal screening recommendations for men who have sex with men.
- World Health Organization. Sexually transmitted infections fact sheet, including global incidence estimates for chlamydia and other curable STIs.
- UK National Health Service. Chlamydia overview: symptoms, testing pathway, and partner-notification process under the UK system.
